The triple reuptake inhibitor DOV216,303 exhibits limited antidepressant-like properties in the differential reinforcement of low-rate 72-second responding assay, likely due to dopamine reuptake inhibition.
Paterson
Neil E
NE
PsychoGenics, Inc., Tarrytown, NY 10591, USA. neil.paterson@psychogenics.com
Balci
Fuat
F
Campbell
Una
U
Olivier
Berend E
BE
Hanania
Taleen
T
D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D001372:Aza Compounds / Q000494:pharmacology*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology*; D016642:Bupropion / Q000494:pharmacology; D003891:Desipramine / Q000494:pharmacology; D003975:Diazepam / Q000494:pharmacology; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology*; D016666:Fluvoxamine / Q000494:pharmacology; D006220:Haloperidol / Q000494:pharmacology; D007099:Imipramine / Q000494:pharmacology; D008297:Male; D010879:Piperazines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012054:Reinforcement, Psychology
C474071:1-(3,4-dichlorophenyl)-3-azabicyclo-(3.1.0)hexane hydrochloride; D000928:Antidepressive Agents; D001372:Aza Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D018765:Dopamine Uptake Inhibitors; D010879:Piperazines; D016642:Bupropion; C043425:vanoxerine; D006220:Haloperidol; D016666:Fluvoxamine; D007099:Imipramine; D003975:Diazepam; D003891:Desipramine